PHP
PHAS

Parkman Healthcare Partners’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Parkman Healthcare Partners’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-110,547
Closed -$371K – 101
2020
Q4 		$371K Buy
+110,547
New +$396K 0.1% 82
2020
Q1 		– Sell
-91,091
Closed -$557K – 81
2019
Q4 		$557K Buy
+91,091
New +$375K 0.16% 66

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Parkman Healthcare Partners's PHAS Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2021, closing a stake of 110,547 shares — an estimated $371K sold.

Parkman Healthcare Partners first reported a position in PHAS in Q4 2019 and held it in 2 quarters. The position peaked at $557K in Q4 2019. 61 funds tracked by Wall St. Rank hold PHAS as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 110,547 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $371K.
  • Parkman Healthcare Partners first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Parkman Healthcare Partners's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $557K in Q4 2019.
  • 61 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.